Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom P Freeman

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Addiction (Abingdon, England)|March 15, 2022
The iCannToolkit: a tool to embrace measurement of medicinal and non-medicinal cannabis use across licit, illicit and cross-cultural settingsValentina Lorenzetti, Chandni Hindocha, Kat Petrilli, et al.
Bjpsych Open|December 12, 2024
A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disordersMarta Di Forti, Benjamin W Bond, Edoardo Spinazzola, et al.
Addiction (Abingdon, England)|May 23, 2022
The iCannTookit: a consensus-based, flexible framework for measuring contemporary cannabis useValentina Lorenzetti, Chandni Hindocha, Kat Petrilli, et al.
Psychological Medicine|April 29, 2020
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controlsMusa Sami, Diego Quattrone, Laura Ferraro, et al.
The International Journal on Drug Policy|July 10, 2021
Standard units for cannabis dose: Why is it important to standardize cannabis dose for drug policy and how can we enhance its place on the public health agenda?Hugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, et al.
Frontiers in Psychiatry|June 7, 2021
Supporting Future Cannabis Policy - Developing a Standard Joint Unit: A Brief Back-Casting ExerciseHugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
The Lancet. Psychiatry|March 24, 2019
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control studyMarta Di Forti, Diego Quattrone, Tom P Freeman, et al.
Psychological Medicine|May 2, 2023
The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control studyEdoardo Spinazzola, Diego Quattrone, Victoria Rodriguez, et al.
Psychological Medicine|March 19, 2020
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control studyDiego Quattrone, Laura Ferraro, Giada Tripoli, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Addiction (Abingdon, England)|March 15, 2022
The iCannToolkit: a tool to embrace measurement of medicinal and non-medicinal cannabis use across licit, illicit and cross-cultural settingsValentina Lorenzetti, Chandni Hindocha, Kat Petrilli, et al.
Bjpsych Open|December 12, 2024
A proof-of-concept analysis of data from the first NHS clinic for young adults with comorbid cannabis use and psychotic disordersMarta Di Forti, Benjamin W Bond, Edoardo Spinazzola, et al.
Addiction (Abingdon, England)|May 23, 2022
The iCannTookit: a consensus-based, flexible framework for measuring contemporary cannabis useValentina Lorenzetti, Chandni Hindocha, Kat Petrilli, et al.
Psychological Medicine|April 29, 2020
Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controlsMusa Sami, Diego Quattrone, Laura Ferraro, et al.
The International Journal on Drug Policy|July 10, 2021
Standard units for cannabis dose: Why is it important to standardize cannabis dose for drug policy and how can we enhance its place on the public health agenda?Hugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, et al.
Frontiers in Psychiatry|June 7, 2021
Supporting Future Cannabis Policy - Developing a Standard Joint Unit: A Brief Back-Casting ExerciseHugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|January 15, 2025
Cannabis Use Cessation and the Risk of Psychotic Disorders: A Case-Control Analysis from the First Episode Case-Control EU-GEI WP2 Study: L'arrêt de l'utilisation du cannabis et le risque de troubles psychotiques: Une analyse cas-témoins tirée de l'étude cas-témoins EU-GEI WP2 centrée sur les premiers épisodes psychotiquesBenjamin W Bond, Bea Duric, Edoardo Spinazzola, et al.
The Lancet. Psychiatry|March 24, 2019
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control studyMarta Di Forti, Diego Quattrone, Tom P Freeman, et al.
Psychological Medicine|May 2, 2023
The association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control studyEdoardo Spinazzola, Diego Quattrone, Victoria Rodriguez, et al.
Psychological Medicine|March 19, 2020
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control studyDiego Quattrone, Laura Ferraro, Giada Tripoli, et al.
Pageof 20